Vascular Solutions (VASC) 39.20 $VASC
Vascular Solutions reports 1Q loss
Automated Insights - Mon Apr 25, 3:53PM CDT
MINNEAPOLIS (AP) _ Vascular Solutions Inc. (VASC) on Monday reported a first-quarter loss of $255,000, after reporting a profit in the same period a year earlier.
VASC: 39.20 (+0.23)
Vascular Solutions Reports First Quarter Results
GlobeNewswire - Mon Apr 25, 3:05PM CDT
-- Revenue increased 14% to $39.4 million, exceeding the top end of guidance
VASC: 39.20 (+0.23)
Vascular Solutions Has Returned 26.1% Since SmarTrend Recommendation (VASC)
Comtex SmarTrend(R) - Mon Apr 18, 1:07PM CDT
SmarTrend identified an Uptrend for Vascular Solutions (NASDAQ:VASC) on February 29th, 2016 at $30.37. In approximately 2 months, Vascular Solutions has returned 26.14% as of today's recent price of $38.31.
VASC: 39.20 (+0.23)
Vascular Solutions, Inc. Issues Recall of Guardian(R) II Hemostasis Valves
GlobeNewswire - Fri Apr 08, 3:05PM CDT
On March 3, 2016, Vascular Solutions, Inc., (Nasdaq:VASC) initiated a nationwide recall of Guardian II hemostasis valves used in catheterization procedures. Specific lots of the products have been recalled because they pose an increased risk of air leakage that may lead to an air embolism, which could result in serious injury or death. This recall only affects the Guardian II hemostasis valves and does not include the Guardian II NC hemostasis valves. No injuries have been reported in association with this issue to date.
VASC: 39.20 (+0.23)
Vascular Solutions, Inc. to Webcast First Quarter Conference Call
GlobeNewswire - Mon Apr 04, 3:05PM CDT
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that it will host a live webcast of its first quarter conference call on Monday, April 25th at 3:30pm CDT. Vascular Solutions' Chief Executive Officer, Howard Root, Chief Financial Officer, James Hennen and VP of Corporate Development, Phil Nalbone, will discuss the company's first quarter results. The company will issue an earnings news release after market close on Monday, April 25th.
VASC: 39.20 (+0.23)
Vascular Solutions to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Fri Apr 01, 3:30PM CDT
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that the Company is scheduled to present at the 15 Annual Needham Healthcare Conference in New York on Tuesday, April 12 at 5:00pm (EDT).
VASC: 39.20 (+0.23)
Amedisys Tops Q4 Earnings, Revenues: Cash Flow Strong
Zacks Equity Research - Zacks Investment Research - Wed Mar 09, 8:30AM CST
Amedisys (AMED) ended 2015 on an outstanding note with its fourth-quarter financials squarely beating the Zacks Consensus Estimate.
VASC: 39.20 (+0.23), AMED: 50.91 (+1.60), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Medtronic Starts Evolut R Trial for High-Risk AS Patients
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 1:10PM CST
Aortic stenosis (AS) patients, who are at high-risk of open surgery, benefit more when implanted with a transcatheter heart valve (THV) like Medtronic's (MDT) CoreValve Evolut R.
MDT: 85.77 (+1.51), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Zimmer Biomet: FDA 510(K) for Implant Product Compatibility
Zacks Equity Research - Zacks Investment Research - Fri Mar 04, 3:10PM CST
Recently, Zimmer Biomet Holdings, Inc. (ZBH) announced Food and Drug Administration's (FDA) 510(k) clearance for the compatibility between two of its implant systems.
ZBH: 120.92 (+2.29), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Integra LifeSciences Global Prospects Bright, Risks Remain
Zacks Equity Research - Zacks Investment Research - Fri Mar 04, 1:00PM CST
Integra (IART) ended 2015 on a satisfactory note with its bottom-line figure surpassing our estimate. However foreign exchange
IART: 77.07 (+1.75), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
BioScrip Posts Wider-than-Expected Q4 Loss, Margins Down
Zacks Equity Research - Zacks Investment Research - Thu Mar 03, 9:00AM CST
BioScrip (BIOS) posted a mixed fourth-quarter 2015 with the top line exceeding our estimate and the bottom line missing the same
BIOS: 2.76 (-0.02), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Genomic Health Breast Cancer Assay Positive in PlanB Trial
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 1:30PM CST
Genomic Health's (GHDX) Oncology DX Recurrence Score (RS) enables physicians to rightly choose patients fit to undergo chemotherapy treatments.
VASC: 39.20 (+0.23), GHDX: 26.59 (+0.11), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
LeMaitre Vascular Raised to Strong Buy on Solid Q4 Results
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 11:30AM CST
On Mar 2, Zacks Investment Research raised LeMaitre Vascular Inc. (LMAT) to a Zacks Rank #1 (Strong Buy).
LMAT: 14.82 (+0.13), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Medtronic (MDT) Wins CE Mark for 3T MR-Safe CRT-Ds (revised)
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 7:08AM CST
In addition to the full line of CRT-Ds, Medtronic's (MDT) MR-safe cardiac rhythm and heart failure devices and leads are now approved for full body scans in both 1.5 and 3T MRI machines in Europe.
MDT: 85.77 (+1.51), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
AmSurg: Strong Q4 Raises Hope amid Bleak Cash Balance
Zacks Equity Research - Zacks Investment Research - Tue Mar 01, 1:20PM CST
AmSurg (AMSG) ended 2015 on an impressive note with its fourth-quarter results squarely beating the Zacks Consensus Estimate.
AMSG: 81.67 (+0.64), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Quest Diagnostics Acquires CLP's Outreach Lab Service
Zacks Equity Research - Zacks Investment Research - Tue Mar 01, 1:15PM CST
Quest Diagnostics Inc.'s (DGX) mergers and acquisitions (M&A) strategy is on a roll. CLP, as the outreach laboratory services provider for HHC, provides clinical lab testing to physicians in Connecticut.
DGX: 80.53 (+0.94), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Is Medtronic's Solitaire the Key to Ischemic Stroke Cure in US?
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 1:45PM CST
A closer look at Medtronic's (MDT) recent history will reveal that it has been making some crucial developments within its thrombectomy product line, particularly with respect to ischemic stroke.
MDT: 85.77 (+1.51), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Affymetrix Misses Q4 Earnings, Beats Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Thu Feb 18, 11:20AM CST
Affymetrix Inc. (AFFX) reported adjusted earnings of 9 cents per share, which missed the Zacks Consensus Estimate by a couple of cents.
HCA: 79.75 (+0.45), VASC: 39.20 (+0.23), AFFX: 14.01 (+0.02), HRC: 52.06 (+0.78)
Chemed Beats Q4 Earnings, Revenues; Cash Balance Strong
Zacks Equity Research - Zacks Investment Research - Thu Feb 18, 11:10AM CST
Chemed (CHE) ended 2015 on an impressive note, with its fourth-quarter results exceeding the Zacks Consensus Estimate of earnings and revenues.
CHE: 133.99 (+1.37), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Vascular Solutions Shares Down 25.0% Since SmarTrend's Sell Call (VASC)
Comtex SmarTrend(R) - Mon Feb 08, 4:19PM CST
SmarTrend identified a Downtrend for Vascular Solutions (NASDAQ:VASC) on January 4th, 2016 at $33.28. In approximately 1 month, Vascular Solutions has returned 24.97% as of today's recent price of $24.97.
VASC: 39.20 (+0.23)
Vascular Solutions reports 1Q loss
Automated Insights - Mon Apr 25, 3:53PM CDT
MINNEAPOLIS (AP) _ Vascular Solutions Inc. (VASC) on Monday reported a first-quarter loss of $255,000, after reporting a profit in the same period a year earlier.
VASC: 39.20 (+0.23)
Vascular Solutions Reports First Quarter Results
GlobeNewswire - Mon Apr 25, 3:05PM CDT
-- Revenue increased 14% to $39.4 million, exceeding the top end of guidance
VASC: 39.20 (+0.23)
Vascular Solutions Has Returned 26.1% Since SmarTrend Recommendation (VASC)
Comtex SmarTrend(R) - Mon Apr 18, 1:07PM CDT
SmarTrend identified an Uptrend for Vascular Solutions (NASDAQ:VASC) on February 29th, 2016 at $30.37. In approximately 2 months, Vascular Solutions has returned 26.14% as of today's recent price of $38.31.
VASC: 39.20 (+0.23)
Vascular Solutions, Inc. Issues Recall of Guardian(R) II Hemostasis Valves
GlobeNewswire - Fri Apr 08, 3:05PM CDT
On March 3, 2016, Vascular Solutions, Inc., (Nasdaq:VASC) initiated a nationwide recall of Guardian II hemostasis valves used in catheterization procedures. Specific lots of the products have been recalled because they pose an increased risk of air leakage that may lead to an air embolism, which could result in serious injury or death. This recall only affects the Guardian II hemostasis valves and does not include the Guardian II NC hemostasis valves. No injuries have been reported in association with this issue to date.
VASC: 39.20 (+0.23)
Vascular Solutions, Inc. to Webcast First Quarter Conference Call
GlobeNewswire - Mon Apr 04, 3:05PM CDT
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that it will host a live webcast of its first quarter conference call on Monday, April 25th at 3:30pm CDT. Vascular Solutions' Chief Executive Officer, Howard Root, Chief Financial Officer, James Hennen and VP of Corporate Development, Phil Nalbone, will discuss the company's first quarter results. The company will issue an earnings news release after market close on Monday, April 25th.
VASC: 39.20 (+0.23)
Vascular Solutions to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Fri Apr 01, 3:30PM CDT
Vascular Solutions, Inc. (Nasdaq:VASC) today announced that the Company is scheduled to present at the 15 Annual Needham Healthcare Conference in New York on Tuesday, April 12 at 5:00pm (EDT).
VASC: 39.20 (+0.23)
Amedisys Tops Q4 Earnings, Revenues: Cash Flow Strong
Zacks Equity Research - Zacks Investment Research - Wed Mar 09, 8:30AM CST
Amedisys (AMED) ended 2015 on an outstanding note with its fourth-quarter financials squarely beating the Zacks Consensus Estimate.
VASC: 39.20 (+0.23), AMED: 50.91 (+1.60), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Medtronic Starts Evolut R Trial for High-Risk AS Patients
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 1:10PM CST
Aortic stenosis (AS) patients, who are at high-risk of open surgery, benefit more when implanted with a transcatheter heart valve (THV) like Medtronic's (MDT) CoreValve Evolut R.
MDT: 85.77 (+1.51), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Zimmer Biomet: FDA 510(K) for Implant Product Compatibility
Zacks Equity Research - Zacks Investment Research - Fri Mar 04, 3:10PM CST
Recently, Zimmer Biomet Holdings, Inc. (ZBH) announced Food and Drug Administration's (FDA) 510(k) clearance for the compatibility between two of its implant systems.
ZBH: 120.92 (+2.29), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Integra LifeSciences Global Prospects Bright, Risks Remain
Zacks Equity Research - Zacks Investment Research - Fri Mar 04, 1:00PM CST
Integra (IART) ended 2015 on a satisfactory note with its bottom-line figure surpassing our estimate. However foreign exchange
IART: 77.07 (+1.75), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
BioScrip Posts Wider-than-Expected Q4 Loss, Margins Down
Zacks Equity Research - Zacks Investment Research - Thu Mar 03, 9:00AM CST
BioScrip (BIOS) posted a mixed fourth-quarter 2015 with the top line exceeding our estimate and the bottom line missing the same
BIOS: 2.76 (-0.02), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Genomic Health Breast Cancer Assay Positive in PlanB Trial
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 1:30PM CST
Genomic Health's (GHDX) Oncology DX Recurrence Score (RS) enables physicians to rightly choose patients fit to undergo chemotherapy treatments.
VASC: 39.20 (+0.23), GHDX: 26.59 (+0.11), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
LeMaitre Vascular Raised to Strong Buy on Solid Q4 Results
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 11:30AM CST
On Mar 2, Zacks Investment Research raised LeMaitre Vascular Inc. (LMAT) to a Zacks Rank #1 (Strong Buy).
LMAT: 14.82 (+0.13), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Medtronic (MDT) Wins CE Mark for 3T MR-Safe CRT-Ds (revised)
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 7:08AM CST
In addition to the full line of CRT-Ds, Medtronic's (MDT) MR-safe cardiac rhythm and heart failure devices and leads are now approved for full body scans in both 1.5 and 3T MRI machines in Europe.
MDT: 85.77 (+1.51), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
AmSurg: Strong Q4 Raises Hope amid Bleak Cash Balance
Zacks Equity Research - Zacks Investment Research - Tue Mar 01, 1:20PM CST
AmSurg (AMSG) ended 2015 on an impressive note with its fourth-quarter results squarely beating the Zacks Consensus Estimate.
AMSG: 81.67 (+0.64), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Quest Diagnostics Acquires CLP's Outreach Lab Service
Zacks Equity Research - Zacks Investment Research - Tue Mar 01, 1:15PM CST
Quest Diagnostics Inc.'s (DGX) mergers and acquisitions (M&A) strategy is on a roll. CLP, as the outreach laboratory services provider for HHC, provides clinical lab testing to physicians in Connecticut.
DGX: 80.53 (+0.94), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Is Medtronic's Solitaire the Key to Ischemic Stroke Cure in US?
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 1:45PM CST
A closer look at Medtronic's (MDT) recent history will reveal that it has been making some crucial developments within its thrombectomy product line, particularly with respect to ischemic stroke.
MDT: 85.77 (+1.51), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Affymetrix Misses Q4 Earnings, Beats Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Thu Feb 18, 11:20AM CST
Affymetrix Inc. (AFFX) reported adjusted earnings of 9 cents per share, which missed the Zacks Consensus Estimate by a couple of cents.
HCA: 79.75 (+0.45), VASC: 39.20 (+0.23), AFFX: 14.01 (+0.02), HRC: 52.06 (+0.78)
Chemed Beats Q4 Earnings, Revenues; Cash Balance Strong
Zacks Equity Research - Zacks Investment Research - Thu Feb 18, 11:10AM CST
Chemed (CHE) ended 2015 on an impressive note, with its fourth-quarter results exceeding the Zacks Consensus Estimate of earnings and revenues.
CHE: 133.99 (+1.37), VASC: 39.20 (+0.23), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Vascular Solutions Shares Down 25.0% Since SmarTrend's Sell Call (VASC)
Comtex SmarTrend(R) - Mon Feb 08, 4:19PM CST
SmarTrend identified a Downtrend for Vascular Solutions (NASDAQ:VASC) on January 4th, 2016 at $33.28. In approximately 1 month, Vascular Solutions has returned 24.97% as of today's recent price of $24.97.
VASC: 39.20 (+0.23)
